Page last updated: 2024-12-07
ru 31156
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
RU 31156: inhibitor or experimental immediate hypersensitivity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 125649 |
CHEMBL ID | 1627190 |
MeSH ID | M0067170 |
Synonyms (10)
Synonym |
---|
ru-31156 |
ru 31156 |
66934-53-0 |
CHEMBL1627190 |
jbt8k7f1eg , |
unii-jbt8k7f1eg |
5-hexyl-7-(s-methanesulfonimidoyl)-9-oxo-9h-xanthene-2-carboxylic acid--2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1) |
DTXSID10985612 |
sudexanox tromethamine |
2-amino-2-(hydroxymethyl)propane-1,3-diol;5-hexyl-7-(methylsulfonimidoyl)-9-oxoxanthene-2-carboxylic acid |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Both RU 31156 and DSCG inhibited anaphylactic bronchoconstriction in the rat, giving bell-shaped dose-response curves." | ( Inhibition of experimental immediate hypersensitivity reactions by a novel xanthone, RU 31156. James, GW; Miller, P, 1978) | 0.96 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (75.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |